What is the clinical evidence from this study?

Study design: Observational. Population: Coronary artery disease (n=47108). Intervention: High polygenic risk score (PRS) for CAD vs. Lower polygenic risk score. Primary outcome: Recommendations for statin therapy per the ACC/AHA among primary prevention patients (p=0.54).

What question did this study set out to answer?

Determine whether contemporary guideline recommendations and clinical management patterns effectively capture high polygenic risk of coronary artery disease in primary prevention.

August 27, 2026Journal of the American College of CardiologyOpen Access

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

Q: What are the key findings of this study?

Among primary prevention patients, high polygenic risk for CAD did not correspond with increased ACC/AHA recommendations for statin therapy (46.2% vs 46.8%, P=0.54).

View Full Paper

Ask AI

Bookmark

Key result

High CAD polygenic risk is not linked to increased guideline-recommended statin eligibility in primary prevention.

P=0.54
n=47,108

Why the study?

Whether polygenic CAD risk is captured by conventional clinical cardiovascular risk assessment paradigms remains unclear, limiting integration of genetic risk into primary prevention guidelines.

Does a high polygenic risk score for CAD correspond with increased guideline-recommended statin eligibility in primary prevention patients?

Population

47,108 individuals across 3 U.S. health care systems, mean age 60 years, 23.4% with prevalent CAD

Design

Observational cohort study

Authors

KAKrishna G. AragamPreventive Cardiology ADAmanda DobbynStatens Serum Institut RJRenae JudyHeart Failure & Transplant

Discussion

Member takes

Implication

Current primary cardiovascular prevention guidelines incompletely capture polygenic susceptibility to CAD, highlighting an opportunity to improve prevention by integrating genetic risk into clinical risk assessment.

Key Points

Determine whether contemporary guideline recommendations and clinical management patterns effectively capture high polygenic risk of coronary artery disease in primary prevention.
Applied a genome-wide coronary artery disease polygenic risk score (PRS) to 47,108 patients across 3 U.S. health care systems.
Assessed statin eligibility under ACC/AHA and USPSTF guidelines alongside actual statin prescription rates among 33,251 primary prevention patients stratified by polygenic risk.
Coronary artery disease PRS strongly associated with prevalent disease (odds ratio: 1.4 per SD increase, p < 0.0001), with the top 20% conferring a 1.9-fold odds of coronary artery disease (p < 0.0001).
Among 33,251 primary prevention patients, high polygenic risk was not associated with increased statin recommendation rates under ACC/AHA (46.2% vs. 46.8%, p = 0.54) or USPSTF guidelines (43.7% vs. 43.7%, p = 0.99), with only marginally higher prescription rates (25.0% vs. 23.8%, p = 0.04).
Designating high polygenic risk as a guideline-based risk-enhancing factor would reclassify an additional 4.1% of primary prevention patients as eligible for statin therapy.

Study Design

Type

Observational (n=47,108)

Multicenter

Yes

Structured PICO

Does a high polygenic risk score for CAD correspond with increased guideline-recommended statin eligibility in primary prevention patients?

Population

47,108 individuals across 3 U.S. health care systems, with a mean age of 60 years, evaluated for polygenic risk of coronary artery disease and statin eligibility.

Exposure

High polygenic risk score (top 20% of PRS) for coronary artery disease

Comparator

Lower polygenic risk score (bottom 80% of PRS)

Outcome

Guideline-recommended statin eligibility (ACC/AHA or USPSTF) and rates of statin therapy

Main Result

Absolute Event Rate: 46.2% vs 46.8%

p-value: p=0.54

Cite This Study

Aragam et al. (2020) conducted an observational in Coronary artery disease (n=47,108). High polygenic risk score (PRS) for CAD vs. Lower polygenic risk score was evaluated on Recommendations for statin therapy per the ACC/AHA among primary prevention patients (p=0.54). Among primary prevention patients, high polygenic risk for CAD did not correspond with increased ACC/AHA recommendations for statin therapy (46.2% vs 46.8%, P=0.54).

synapsesocial.com/papers/6a905558ae93a8619753ebdd https://doi.org/10.1016/j.jacc.2020.04.027

View Full Paper

Ask AI

Bookmark

August 27, 2026Journal of the American College of CardiologyOpen Access

Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease

View Full Paper

Ask AI

Bookmark

Key result

High CAD polygenic risk is not linked to increased guideline-recommended statin eligibility in primary prevention.

P=0.54
n=47,108

Why the study?

Whether polygenic CAD risk is captured by conventional clinical cardiovascular risk assessment paradigms remains unclear, limiting integration of genetic risk into primary prevention guidelines.

Does a high polygenic risk score for CAD correspond with increased guideline-recommended statin eligibility in primary prevention patients?

Population

47,108 individuals across 3 U.S. health care systems, mean age 60 years, 23.4% with prevalent CAD

Design

Observational cohort study

Authors

KAKrishna G. AragamPreventive Cardiology ADAmanda DobbynStatens Serum Institut RJRenae JudyHeart Failure & Transplant

Discussion

Member takes

Implication

Key Points

Determine whether contemporary guideline recommendations and clinical management patterns effectively capture high polygenic risk of coronary artery disease in primary prevention.
Applied a genome-wide coronary artery disease polygenic risk score (PRS) to 47,108 patients across 3 U.S. health care systems.
Assessed statin eligibility under ACC/AHA and USPSTF guidelines alongside actual statin prescription rates among 33,251 primary prevention patients stratified by polygenic risk.
Coronary artery disease PRS strongly associated with prevalent disease (odds ratio: 1.4 per SD increase, p < 0.0001), with the top 20% conferring a 1.9-fold odds of coronary artery disease (p < 0.0001).
Among 33,251 primary prevention patients, high polygenic risk was not associated with increased statin recommendation rates under ACC/AHA (46.2% vs. 46.8%, p = 0.54) or USPSTF guidelines (43.7% vs. 43.7%, p = 0.99), with only marginally higher prescription rates (25.0% vs. 23.8%, p = 0.04).
Designating high polygenic risk as a guideline-based risk-enhancing factor would reclassify an additional 4.1% of primary prevention patients as eligible for statin therapy.

Study Design

Type

Observational (n=47,108)

Multicenter

Yes

Structured PICO

Does a high polygenic risk score for CAD correspond with increased guideline-recommended statin eligibility in primary prevention patients?

Population

47,108 individuals across 3 U.S. health care systems, with a mean age of 60 years, evaluated for polygenic risk of coronary artery disease and statin eligibility.

Exposure

High polygenic risk score (top 20% of PRS) for coronary artery disease

Comparator

Lower polygenic risk score (bottom 80% of PRS)

Outcome

Guideline-recommended statin eligibility (ACC/AHA or USPSTF) and rates of statin therapy

Main Result

Absolute Event Rate: 46.2% vs 46.8%

p-value: p=0.54

Cite This Study

synapsesocial.com/papers/6a905558ae93a8619753ebdd https://doi.org/10.1016/j.jacc.2020.04.027

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark